VA1213

VA1213 is a small molecule, selective cyclooxygenase-2 (COX-2) inhibitor belonging to the vicinal diaryl-substituted heterocyclic class. It exhibits potent in vitro antitumor activity, particularly against colorectal and breast carcinoma cell lines such as HT-29 and MDA-MB-231. The compound's mechanism of action involves the induction of G₀/G₁ phase cell cycle arrest and apoptosis via caspase-3 activation. Furthermore, VA1213 interferes with oncogenic signaling by suppressing the phosphorylation of AKT and ERK1/2, which are downstream components of the epidermal growth factor receptor (EGFR) pathway, notably without directly inhibiting the EGFR protein itself. Compared to the established COX-2 inhibitor celecoxib, VA1213 demonstrates a more gradual, time-dependent cytotoxic effect and enhanced inhibition of cell migration at sub-cytotoxic concentrations.